Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility

  title={Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility},
  author={Ronnen H. Segman and Uriel Heresco-Levy and Boris Finkel and Roi Inbar and Tal Neeman and Michael Schlafman and Abraham Dorevitch and Avraham Yakir and Arturo G. Lerner and Tanya Goltser and A Shelevoy and Bernard Lerer},
Abstract. Rationale: Tardive dyskinesia (TD) is a long-term adverse effect of dopamine receptor blockers. The dopamine D3 receptor gene (DRD3) ser9gly polymorphism has been previously associated with susceptibility to TD. Serotonin receptor antagonism has been proposed as a common mechanism contributing to the low extrapyramidal effects profile of atypical antipsychotic drugs. Objectives: To examine the association of a functional polymorphism in the 5-HT2C receptor gene (HT2CR) with TD and the… 

Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia

Findings suggest that the above polymorphic loci do not contribute significantly to risk for TD, and further examination of loci that yielded positive results at a trend level and investigation of other candidate genetic loci coding for antipsychotic drug targets is warranted.

There is no evidence for an association between the serotonin receptor 3A gene C178T polymorphism and tardive dyskinesia in Korean schizophrenia patients

The findings of the present study do not support the involvement of the 5-HTR3A gene C178T polymorphism in TD in Korean schizophrenia subjects.

Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients.

The present study investigates 12 polymorphisms spanning the DRD2 gene and their association with TD in European Caucasian and African-American samples and suggests thatDRD2 may be involved in TD in the Caucasian population, although further studies are warranted.

Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients

An association was observed between polymorphisms in H TR2A and HTR2C genes and occurrence of acute EPS in schizophrenic patients treated with perphenazine monotherapy.

Association Study between Tryptophan Hydroxylase 2 Gene -703G/T Polymorphism and Tardive Dyskinesia

The present study does not support that TPH2 gene -703G/T polymorphism is involved in TD of the Korean schizophrenia subjects.

Association between the Ser9Gly Polymorphism of the Dopamine D3 Receptor Gene and Tardive Dyskinesia in Chinese Schizophrenic Patients

The results suggest that the presence of the DRD3ser-gly genotype may be a risk factor for the development of TD in patients treated with antipsychotics.

Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype.

It is confirmed that genetic variability in HTR(2A) contributes a small but significant degree of risk for the expression of TD, particularly in older patients and specifically for the non-orofacial (limb-truncal) type.

Gene Association Studies of Schizophrenia and Tardive Dyskinesia

This analysis investigated the GABAA receptor γ2 subunit gene GABRG2, the dopamine receptor gene DRD3, and the Brain-derived neurotrophic factor gene BDNF that is required for D3 expression by genotyping polymorphisms spanning and surrounding these genes for association with SCZ, as well as suicidal behaviour.

Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients

Results confirm previously reported associations between the H TR2C 23Ser allele and EPS occurrence and suggest the novel finding of an HTR2C haplotype association with EPS in male chronic schizophrenic patients.



Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia

The results support the report by Steen et al (1997) of an association between DRD3 and TD in schizophrenia patients and extend the report on the role of age at first antipsychotic treatment in this disease.

Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

Investigation of the genetic variation of the dopamine D3 receptor gene (DRD3) as a putative risk factor for TD in schizophrenic patients receiving long-term anti-psychotic drug therapy indicates that autosomal inheritance of two polymorphic Ser9Gly alleles, but not homozygosity for the wild-type allele (1-1 genotype), is a susceptibility factor for the development of TD.

Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia

Dopamine D3 receptor variant and tardive dyskinesia

Abstract In the search for genetic factors contributing to tardive dyskinesia, dopamine receptor genes are considered major candidates. The dopamine D3 receptor is of primary interest as dopamine D3

Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients.

The non-significant tendency in this sample towards an over-representation of allele 2 and the 2-2 genotype among schizophrenic patients with TD is in line with initial report as well as recent studies by others, indicating that the Gly-9 allele of DRD3 may be a susceptibility factor for the development of TD in neuroleptic-treated individuals with schizophrenia.

The Role of Serotonin in Antipsychotic Drug Action

  • H. Meltzer
  • Psychology, Medicine
  • 1999

Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C).

Concentration-response curves for 5-HT were not significantly different in oocytes expressing either form of the receptor, suggesting that the 5- HT2Ccys and5-HT2Cser receptor proteins may not differ in their responses to serotonin under baseline physiological conditions.

O-11-5 Tardive dyskinesia and ethnicity: Review of the literature

Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia.

  • D. Casey
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 1998
Sociodemographic, behavioral, and clinical predictors of TD are useful in identifying a subset of schizophrenic individuals who would benefit from treatment with clozapine, the prototype atypical antipsychotic whose efficacy and motor side effect profile are superior to those of chlorpromazine.